Development of a network model to implement the HPV vaccination coverage
Keywords:
Human Papillomavirus; vaccination; HPV vaccination; gender gap; prevention strategiesAbstract
Background. The vaccination coverage of a population is the usual indicator of the effectiveness of vaccination strategies. The study aims to evaluate the effectiveness of an organizational and communication network to implement Human Papilloma Virus (HPV) vaccination coverage both in males and females in the Center Tuscany Local Health Authority.
Study design. Experimental study.
Materials and methods. In January 2022, a retrospective study was conducted on anti-HPV vaccine coverage (full cycle), of those born from 2007 to 2010, in the Empoli Territorial Area of Florence (240 thousand inhabitants) under the Center Tuscany Local Health Authority. In February 2022, a project (meetings with general practitioners and pediatricians, communication through local media, increased opening hours of vaccination clinics and continuous monitoring of vaccination status) started to recover the females and males non-compliant; in the first five months, in addition to guaranteeing the offer to the reference cohort, it aimed to recover the 2007, 2008 and 2009 cohorts, while in the following six months the anti-HPV vaccine offer was expanded for the 2010 cohort.
Results. In January 2022, for all cohorts the average total coverages were 49.2% (49.1% for females and 49.5% for males), while in December 2022 they were 63.9% (65.8% for females and 62.3% for males). Coverage increased by 15.6% (+14.2% for females and +16.8% for males) for the 2007 birth cohort, by 22.3% (+20.6% for females and +23.7% for males) for the 2008 cohort and by 20.9% (+31.4% for females and +10.6% for males) for the 2009 cohort.
Conclusions. This model in force in the whole Center Tuscany Local Health Authority for a few years and already activated in the previous Local Health Authority of Empoli, now called Empoli Territorial Area, has allowed to implement the Human Papilloma Virus vaccine coverage for both genders.
References
1. Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: From promise to practice. PLoS Med. 2017 Jun 27; 14(6): e1002325. doi: 10.1371/journal. pmed.1002325.
2. Shin H, Choi S, Lee JY. An Integrative Review of the Influence on Human Papillomavirus Vaccination Adherence among Adolescents. Healthcare (Basel). 2023 Sep 13; 11(18): 2534. doi: 10.3390/healthcare11182534.
3. Dunne EF, Park IU. HPV and HPV-associated diseases.
Infect Dis Clin North Am. 2013 Dec; 27(4): 765-78. doi:
10.1016/j.idc.2013.09.001.
4. Charde SH, Warbhe RA. Human Papillomavirus Prevention by Vaccination: A Review Article. Cureus. 2022 Oct 7; 14(10): e30037. doi: 10.7759/cureus.30037.
5. Maver PJ, Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Vaccine. 2018 Aug 28; 36(36): 5416-423. doi: 10.1016/j.
vaccine.2017.07.113.
6. Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021 Sep 30; 224(12 Suppl 2): S367-S378. doi: 10.1093/infdis/jiaa621
7. Restivo V, Minutolo G, Maranto M, Maiorana A, Vitale F, Casuccio A, Amodio E. Impact of Preventive Strategies on HPV-Related Diseases: Ten-Year Data from the Italian Hospital Admission Registry. Cancers (Basel). 2023 Feb 24; 15(5): 1452. doi: 10.3390/cancers15051452.
8. Milano G, Guarducci G, Nante N, Montomoli E, Manini I. Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap? Vaccines (Basel). 2023 Jun 4; 11(6): 1060. doi: 10.3390/vaccines11061060.
9. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019; 15(1): 146-55. doi: 10.1080/21645515.2018.1512453.
10. Wang WV, Kothari S, Skufca J, Giuliano AR, Sundström K, Nygård M, et al.et al. Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines. 2022 Dec; 21(12): 1799-1817. doi: 10.1080/14760584.2022.2129615.
11. Cataldi JR, O’Leary ST, Markowitz LE, Allison MA, Crane LA, Hurley LP, et al.et al. Changes in Strength of Recommendation and Perceived Barriers to Human Papillomavirus Vaccination: Longitudinal Analysis of Primary Care Physicians, 2008-2018. J Pediatr. 2021 Jul; 234: 149-157.e3. doi: 10.1016/j.jpeds.2021.03.002.
12. Lake P, Fuzzell L, Brownstein NC, Fontenot HB, Michel A, McIntyre M, et al. HPV vaccine recommendations by age: A survey of providers in federally qualified health centers. Hum Vaccin Immunother. 2023 Dec 31; 19(1): 2181610. doi: 10.1080/21645515.2023.2181610.
13. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019; 68(32): 698-702. doi: 10.15585/mmwr. mm6832a3.
14. Bogani G, Ghelardi A, Sopracordevole F, Annoni M, Ciavattini A, Giannella L, et al. Human papillomavirus (HPV) vaccination: a call for action in Italy. Int J Gynecol
Cancer. 2023 Jul 3; 33(7): 1132-9. doi: 10.1136/ijgc-2023004275.
15. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009 Dec; 115(3 Suppl): S15-23. doi: 10.1016/j.ygyno.2009.09.021.
16. Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Pérez N, Jit M, et al. Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs.
Vaccine. 2022 Sep 2; 40(37): 5413-32. Doi: 10.1016/j. vaccine.2022.06.065.
17. Gilca V, Salmerón-Castro J, Sauvageau C, Ogilvie G, Landry M, Naus M, Lazcano, et al. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact. Vaccine. 2018 Aug 6; 36(32 Pt A): 4800-5. doi: 10.1016/j.vaccine.2018.02.004.
18. Zhou X, Sun L, Yao X, Li G, Wang Y, Lin Y. Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine. Front Immunol. 2020 Jul 10; 11: 1434. doi: 10.3389/ fimmu.2020.01434.
19. Mavundza EJ, Iwu-Jaja CJ, Wiyeh AB, Gausi B, Abdullahi LH, Halle-Ekane G, et al. A Systematic Review of Interventions to Improve HPV Vaccination Coverage. Vaccines (Basel). 2021 Jun 23; 9(7): 687. doi: 10.3390/ vaccines9070687.
20. Chandeying N, Thongseiratch T. Systematic review and meta-analysis comparing educational and reminder digital interventions for promoting HPV vaccination uptake. NPJ Digit Med. 2023 Aug 29; 6(1): 162. doi: 10.1038/s41746023-00912-w.
21. Walling EB, Dodd S, Bobenhouse N, Reis EC, Sterkel R, Garbutt J. Implementation of Strategies to Improve Human Papillomavirus Vaccine Coverage: A Provider Survey.
Am J Prev Med. 2019 Jan; 56(1): 74-83. doi: 10.1016/j. amepre.2018.07.038.
22. Restivo V, Minutolo G, Maranto M, Maiorana A, Vitale F,
Casuccio A, et al. Impact of Preventive Strategies on HPVRelated Diseases: Ten-Year Data from the Italian Hospital Admission Registry. Cancers (Basel). 2023 Feb 24; 15(5): 1452. doi: 10.3390/cancers15051452.
23. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021; Jan 20; 8: 552028. doi: 10.3389/fpubh.2020.552028.
24. Gualano MR, Bert F, Voglino G, Buttinelli E, D’Errico MM, De Waure C, et al; Collaborating Group. Attitudes towards compulsory vaccination in Italy: Results from the NAVIDAD multicentre study. Vaccine. 2018; 36(23): 3368-74. doi: 10.1016/j.vaccine.2018.04.029.
25. Schlenker B, Schneede P. The Role of Human Papilloma Virus in Penile Cancer Prevention and New Therapeutic Agents. Eur Urol Focus. 2019; 5(1): 42-5. doi: 10.1016/j.
euf.2018.09.010.
26. Eun TJ, Perkins RB. Screening for Cervical Cancer. Med Clinics North Am. 2020 Nov; 104(6): 1063-78. doi:
10.1016/j.mcna.2020.08.006.
27. Vaccination against Papillomavirus (HPV) – Vaccine coverage. Ministry of Health. Available from: https://www.salute. gov.it/imgs/C_17_tavole_27_1_7_file.pdf [Last accessed: 2024 Feb 12].
28. Sorrentino M, Mercogliano M, Esposito F, Lamberti AM, Buonocore G, Riganti C, et al. Identification of organi zational barriers to HPV vaccination uptake in medical students in southern Italy: a cross-sectional study. Front Public Health. 2023 Nov 17; 11:1272630. doi: 10.3389/ fpubh.2023.1272630.
29. Cartmell KB, Mzik CR, Sundstrom BL, Luque JS, White A, Young-Pierce J. HPV Vaccination Communication Messages, Messengers, and Messaging Strategies. J Cancer Educ. 2019 Oct; 34(5):1014-1023. doi: 10.1007/s13187018-1405-x.
30. Moss JL, Reiter PL, Rimer BK, Ribisl KM, Brewer NT. Summer Peaks in Uptake of Human Papillomavirus and Other Adolescent Vaccines in the United States. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):274-81. doi: 10.1158/1055-9965.EPI-15-0574.
31. Karafillakis E, Simas C, Jarrett C, Verger P, Peretti-Watel P, Dib F, De Angelis S, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019; 15(7-8): 1615-27. doi: 10.1080/21645515.2018.1564436.
32. Marcellusi A, Mennini FS, Sciattella P, Favato G. Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data. Eur J Health Econ. 2021 Dec; 22(9): 1371-9. doi: 10.1007/ s10198-021-01317-w.
33. Napolitano F, Pelullo CP, Della Polla G, Angelillo IF. HPV Vaccination Attitudes and Behaviors among General Practitioners in Italy. Vaccines (Basel). 2021 Jan 19; 9(1): 63. doi: 10.3390/vaccines9010063.
34. Napolitano F, Navaro M, Vezzosi L, Santagati G, Angelillo IF. Primary care pediatricians’ attitudes and practice towards HPV vaccination: A nationwide survey in Italy. PLoS One. 2018 Mar 29; 13(3): e0194920. doi: 10.1371/journal. pone.0194920.
35. Tran NT, Phan TNT, Pham TT, Le TT, Le HM, Nguyen DT, et al. Urban-rural disparities in acceptance of human papillomavirus vaccination among women in Can Tho, Vietnam. Ann Ig. 2023 Nov-Dec; 35(6): 641-59. doi: 10.7416/ ai.2023.2575. Epub 2023 Jun 15.
36. Wähner C, Hübner J, Meisel D, Schelling J, Zingel R, Mihm S, et al. Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic. Infection. 2023 Oct; 51(5): 1293-1304. doi: 10.1007/s15010-02301978-0.
37. Gabutti G, d’Anchera E, De Motoli F, Savio M, Stefanati A. Human Papilloma Virus Vaccination: Focus on the Italian Situation. Vaccines (Basel). 2021 Nov 23; 9(12): 1374. doi: 10.3390/vaccines9121374.
38. Spînu AD, Anghel RF, Marcu DR, Iorga DL, Cherciu A, Mischianu DLD. HPV vaccine for men: Where to?. Exp Ther Med. 2021 Nov; 22(5): 1266. doi: 10.3892/ etm.2021.10701.
39. European Centre for Disease Prevention and Control (ECDC). Guidance on HPV Vaccination in EU Countries:
Focus on Boys, People Living with HIV and 9-Valent HPV Vaccine Introduction, 2020. Stockholm, Sweden: ECDC; 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Giovanni Guarducci, Marinella Chiti, Dimitri Carlo Fattore, Raffaele Caldararo, Gabriele Messina, Paolo Filidei, Nicola Nante (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.